𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia

✍ Scribed by Stewart A. Factor; Eric S. Molho; Sharon Evans; Paul J. Feustel


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
107 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Efficacy of botulinum toxin type B (BoNT B) for the treatment of type A‐resistant (AR) and non‐A‐resistant (NAR) cervical dystonia (CD) has been demonstrated in several single injection studies. There is little data available on long‐term therapy with repeated injection sessions and it is unknown if AR and NAR patients respond in a similar manner over time. To evaluate the long‐term efficacy and safety of BoNT B in AR and NAR CD patients, we carried out a prospective, open‐label study examining 10 repeated dosing sessions of BoNT B in 34 patients with CD (15 AR and 19 NAR). Dosing was started at 10,000 units and could be increased to 25,000. Assessments included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and a patient global assessment at each baseline (injection) and Week 4 (peak effect) visit. Change in TWSTRS total was the primary efficacy end point. Data was analyzed using repeated‐measures analysis of variance. BoNT B therapy resulted in an overall significant improvement of CD (P < 0.001) and improvement was seen in all 10 individual sessions (2.5 years). The magnitude of response decayed over time (P < 0.001). There was no difference between AR and NAR patients with regard to dose, treatment effect, or decay in response. The AR group perceived (patient global) treatment as being less effective (P = 0.047). Dry mouth frequency decreased with each session despite increasing doses whereas flu‐like syndrome and weakness increased. BoNT B therapy provides long‐term benefit for CD patients but the magnitude of response diminishes over time. The cause of this decay is probably multifactorial. AR and NAR CD patients respond in a similar fashion. © 2005 Movement Disorder Society


📜 SIMILAR VOLUMES


Long-term safety, efficacy, dosing, and
✍ Brian Berman; Lauren Seeberger; Rajeev Kumar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Short‐term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long‐term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, t

BotB (botulinum Toxin type B): Evaluatio
✍ Dr. Daniel D. Truong; Paul A. Cullis; Christopher F. O'Brien; Martin Koller; Tim 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, open‐label, dose‐escalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses

Safety and efficacy of botulinum toxin t
✍ Charles H. Adler; Stephen F. Bansberg; Kari Krein-Jones; Joseph G. Hentz 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

## Abstract This single‐site, open‐label, dose‐finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT‐B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. Three patients received a total of 50 U (25 U per vocal fold); the same three subsequen

Comparison of treatment of tardive dysto
✍ Dr. Allison Brashear; Walter T. Ambrosius; George J. Eckert; Eric R. Siemers 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB

To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypo

Efficacy and safety of botulinum type A
✍ Daniel Truong; Drake D. Duane; Joseph Jankovic; Carlos Singer; Lauren C. Seeberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double‐blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. Ei

Botulinum toxin type B vs. type A in tox
✍ Eric J. Pappert; Terry Germanson 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract The objective of this study was to compare efficacy, safety, and duration of botulinum toxin type A (BoNT‐A) and type B (BoNT‐B) in toxin‐naïve cervical dystonia (CD) subjects. BoNT‐naïve CD subjects were randomized to BoNT‐A or BoNT‐B and evaluated in a double‐blind trial at baseline a